Funded Tech Companies
Excalipoint Therapeutics
Researching who backed Excalipoint Therapeutics? Eisai, 5Y Capital and Hony Capital joined the equity holders in this biopharmaceutical company.
Company Overview
Company Name
Excalipoint Therapeutics
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
Li Yuan (No. 668 Xinzhai Road), Jing'an District 1709
Shanghai, Undisclosed
China
Shanghai, Undisclosed
China
Phone
Undisclosed
Website
Email Address
Company Background Information
Overview
Excalipoint Therapeutics is a clinical-stage biotechnology company dedicated to the discovery and development of next-generation innovative T-cell engager (TCE) therapies to address unmet medical needs globally. Centered on multiple proprietary TCE technology platforms, including TOPAbody Platform, T-Cell Immune Shield Platform and TCE Probody Platform, the company is committed to developing novel T-cell based therapeutics with greater differentiation and stronger clinical potential to overcome treatment barriers of existing therapies. With six pipeline programs across oncology and immunology, its lead candidate EXP011(CTM012) is in Phase I/II trials for solid tumors.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
3/18/2026
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Lei Fang
Company Investors
- Eisai
- 5Y Capital
- Hony Capital
- Med-Fine Capital
- LAV Fund
- HongShan
- Co-win Healthcare Fund
- Centurium Capital
- Yuanbio Venture Capital
Browse more funded tech companies:
Excalibur Electronics | Excarta
Share this article
About Our VC Funding Database
The company data above is provided by VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs